eli lilly glp 1 direct US approves new oral weight-loss pill developed by | US news Lilly markets single-dose Zepbound vials

Remaining Scope for Side-Effect Improvement Retatrutide is a triple-action therapy that, like Lillys Mounjaro and Zepbound drugs, targets glucagon-like peptide-1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, while also acting on the glucagon receptor

After reading the first section you should already understand why, but lets recap it here

The program which runs from July 1, 2026 through December 31, 2027 is designed to improve access to obesity treatment while expanding the use of medications that have been shown to help patients lose weight and reduce the risk of obesity-related health conditions

Wegovy is typically prescribed for adults within a specific BMI range, or with other weight-related health conditions like high blood pressure or type 2 diabetes